H.R. 7828 · 117th Congress
Price Relief, Innovation, and Competition for Essential Drugs Act
- Stage
- In committee
- Sponsor
- Jan Schakowsky
- Introduced
- 2022-05-18
- Latest action
- 2022-05-18 · Introduced in House
Summary
Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act
This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period.
This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.